Management of Postpartum Hemorrhage

Immediate First-Line Management

The American College of Obstetricians and Gynecologists recommends administering intravenous tranexamic acid 1 g over 10 minutes within 3 hours of birth alongside oxytocin 5-10 IU (IV or IM), initiate uterine massage and bimanual compression, and begin fluid resuscitation with physiologic electrolyte solutions 1, 2
Tranexamic acid must be given within 3 hours of birth—effectiveness decreases by approximately 10% for every 15-minute delay, and administration beyond 3 hours may be harmful 1, 2

Pharmacological Management

A second dose of TXA 1 g IV can be given if bleeding continues after 30 minutes or restarts within 24 hours 1, 3
TXA should be administered in all cases of PPH regardless of etiology (uterine atony, trauma, retained tissue) 1
Methylergonovine 0.2 mg IM is contraindicated in hypertensive patients (>10% risk of vasoconstriction and severe hypertension) 1, 4
Methylergonovine should be avoided in women with asthma due to bronchospasm risk 3

Mechanical and Surgical Interventions

Intrauterine balloon tamponade should be implemented before proceeding to surgery or interventional radiology 1, 2
Pelvic pressure packing is effective for acute uncontrolled hemorrhage stabilization, can remain for 24 hours 2
Non-pneumatic antishock garment can be used for temporary stabilization while arranging definitive care 1
Uterine compression sutures (B-Lynch or similar brace sutures) can be used to control bleeding 1, 2
Arterial embolization is particularly useful when no single bleeding source is identified, requires hemodynamic stability for transfer 2, 5

Resuscitation and Blood Product Management

Massive transfusion protocol should be initiated if blood loss exceeds 1,500 mL 2
Packed RBCs, fresh frozen plasma, and platelets should be transfused in fixed ratio 2
Do not delay transfusion waiting for laboratory results in severe bleeding 2, 3
Target hemoglobin >8 g/dL and fibrinogen ≥2 g/L during active hemorrhage 2

Essential Supportive Measures

Maintain normothermia: Warm all infusion solutions and blood products; use active skin warming (clotting factors function poorly at lower temperatures) 2
Administer oxygen in severe PPH, although the specific details are not provided in the cited references, oxygen administration is a standard practice 4
Re-dose prophylactic antibiotics if blood loss exceeds 1,500 mL 2
Continue hemodynamic monitoring for at least 24 hours post-delivery due to significant fluid shifts that may precipitate heart failure in women with structural heart disease 1, 4

Special Considerations

Anticoagulated patients with mechanical heart valves should switch from oral anticoagulants to LMWH/UFH from 36 weeks gestation 4
Discontinue UFH 4-6 hours before planned delivery 4
If emergent delivery is required on therapeutic anticoagulation, consider protamine (partially reverses LMWH) 4
Caesarean delivery is preferred to reduce fetal intracranial hemorrhage risk 4
Monitor for complications: renal failure, liver failure, infection, Sheehan syndrome 2
Early ambulation with elastic support stockings can reduce thromboembolism risk 4
Consider thromboprophylaxis after bleeding controlled, especially with additional VTE risk factors 3

Management of Postpartum Hemorrhage Based on Cited Facts

Etiology-Specific Management and Imaging Considerations

The American College of Radiology recommends that tone (uterine atony), the most common cause of postpartum hemorrhage (>75% of cases), be treated with uterotonic drugs and uterine massage, and that trauma (lacerations, rupture) requires careful visual inspection and surgical repair, with CT with IV contrast useful for localizing bleeding in hemodynamically stable patients 6
The American College of Radiology suggests that CT with IV contrast is useful in hemodynamically stable patients to localize bleeding sources, particularly for intra-abdominal hemorrhage, and that small (<4 cm) subfascial and bladder flap hematomas may not be clinically significant 6
According to the American College of Radiology, a >5 cm bladder flap hematoma should raise suspicion for uterine dehiscence, and ultrasound can be used to diagnose retained products of conception 6

Postpartum Hemorrhage Management

Pharmacological Interventions

The European Respiratory Journal recommends avoiding prostaglandin F2α in women with asthma due to the risk of bronchoconstriction 7

Special Considerations

According to Blood advances, active management of the third stage with oxytocin is critical in anticoagulated patients, as primary hemostasis mechanism is myometrial contraction, not coagulation 8

Management of Postpartum Hemorrhage

Pharmacological Interventions

The American Society of Anesthesiologists recommends administering oxytocin 5-10 IU slow IV or IM immediately for postpartum hemorrhage treatment, with the IV route being more effective than IM 9
Administering oxygen to achieve arterial oxygen saturation ≥95% is crucial in severe postpartum hemorrhage, as stated by the European Society of Cardiology 10

Special Considerations

The American College of Obstetricians and Gynecologists suggests that manual removal of placenta should NOT be routinely performed except in cases of severe and uncontrollable postpartum hemorrhage, as recommended by the Anaesthesia journal 9

Postpartum Hemorrhage: Monitoring and Management of Coagulopathy

Impact of PPH on Coagulopathy

Postpartum hemorrhage (PPH) directly induces acute, unpredictable coagulopathy regardless of the underlying obstetric cause; therefore early coagulation monitoring and aggressive fibrinogen replacement are essential to prevent progression to massive hemorrhage. 11
Hyperfibrinolysis is frequently present in the early phase of PPH and contributes to ongoing bleeding. 11
Coagulopathy can develop with any obstetric etiology, so systematic monitoring is required even when the bleeding source appears straightforward. 11
In atonic or traumatic bleeds, early coagulopathy is less common unless diagnosis is delayed; clinical assessment alone cannot reliably exclude coagulopathy. 11

Monitoring Strategies

Fibrinogen is the single most important laboratory parameter to monitor in PPH because it is the most common factor deficiency and declines rapidly during active bleeding. 11
Viscoelastic hemostatic assays (VHA) should be employed in all hospital‑based maternity units to provide rapid, point‑of‑care assessment of coagulation status. (Expert consensus) 11
Interpretation of VHA results should focus on the fibrinogen assay, with fibrinogen replacement prioritized when the assay is low. (Expert consensus) 11
VHA measurements must be repeated whenever bleeding persists to guide ongoing therapy. (Expert consensus) 11

Initial Blood Component Therapy (Blood Loss < 4 Units RBC)

In atonic or traumatic PPH without early laboratory evidence of coagulopathy, fresh frozen plasma (FFP) should be withheld until at least 4 units of packed red blood cells (RBC) have been transfused. (Expert consensus) 11
If early screening indicates coagulopathy, cryoprecipitate or fibrinogen concentrate may be administered before RBC transfusion. (Expert consensus) 11
Protocol‑driven early use of FFP in these scenarios often leads to unnecessary transfusion volume. (Expert consensus) 11

Massive Transfusion Strategy (≥ 4 Units RBC or > 1500 mL)

After 4 units of RBC have been given and bleeding continues without available coagulation results, administer 4 units of FFP and maintain a 1:1 RBC:FFP ratio until definitive hemostatic testing is obtained. (Expert consensus) 11

Fibrinogen Replacement

Prioritize fibrinogen repletion using cryoprecipitate or fibrinogen concentrate when fibrinogen levels are low; repeat dosing is required if bleeding persists. (Expert consensus) 11
A recent feasibility trial demonstrated that issuing cryoprecipitate before FFP in the first‑issued hemorrhage pack is practical and may improve early fibrinogen correction. (Level II evidence) 11

Platelet Transfusion

Platelet transfusion is seldom needed unless estimated blood loss exceeds 5000 mL or the platelet count falls below 75 × 10⁹/L. (Expert consensus) 11
When the platelet count is < 75 × 10⁹/L, transfuse platelets to support hemostasis. (Expert consensus) 11

Antifibrinolytic Therapy

Administer tranexamic acid 1 g intravenously over 10 minutes within 3 hours of delivery for all cases of PPH, irrespective of etiology. (Expert consensus) 11

Decision to Cease Blood Component Therapy

Stop transfusing blood components once bleeding has ceased, even if laboratory or VHA values remain abnormal; interpret test results in the clinical context and avoid unnecessary transfusion. (Expert consensus) 11

Evidence‑Based Laboratory and Transfusion Management for Secondary Postpartum Hemorrhage

Laboratory Assessment

Obtain a complete blood count, coagulation panel (PT/PTT, fibrinogen), blood group and screen, and a venous blood gas to allow rapid hemoglobin measurement and to detect lactate > 2 mmol/L, which signals shock. 12, 13

Point‑of‑Care Testing

Use point‑of‑care (POC) testing rather than conventional laboratory analysis because POC provides a faster turnaround time during active hemorrhage. 12, 13, 14

Massive Transfusion Protocol

Activate a massive transfusion protocol when estimated blood loss exceeds 1,500 mL and transfuse packed red blood cells, fresh‑frozen plasma, and platelets in a 1:1:1 ratio. 15

Coagulation Product Management

Withhold fresh‑frozen plasma (FFP) until at least 4 units of packed red blood cells have been given if bleeding persists and coagulation results are not yet available, to avoid unnecessary early FFP transfusion. 12, 13, 14, 16
After 4 units of packed red blood cells, administer 4 units of FFP and maintain a 1:1 RBC‑to‑FFP ratio until laboratory coagulation data become available. 12, 13, 14, 16
Give cryoprecipitate or fibrinogen concentrate when fibrinogen levels fall below 2–3 g/L in the setting of ongoing bleeding. 12, 13, 14, 16

Intrauterine Balloon Tamponade: Device Selection and Placement Guidelines

Device Selection

Commercially available intrauterine balloon catheters (e.g., Bakri balloon, BT‑Cath, or equivalent devices) that are specifically designed for postpartum hemorrhage should be used for tamponade. 17

Placement Technique

Vaginal Delivery

A thorough pelvic examination must be performed before balloon insertion to exclude cervical or vaginal lacerations that could contribute to ongoing bleeding. 17

Cesarean Delivery

The deflated balloon catheter should be introduced directly into the uterine cavity through the hysterotomy before uterine closure. 17
After inflation, the hysterotomy incision is closed around the catheter shaft to secure the device in place. 17

Management When Balloon Tamponade Fails

If hemorrhage persists despite correct balloon placement, bilateral uterine artery ligation is recommended as the next surgical step. 17

Evidence‑Based Management of Active Postpartum Hemorrhage

Temperature Management

Maintaining normothermia by warming all infusion solutions and blood products and using active skin warming is essential because clotting factor activity declines markedly below 36 °C. 18

Activation of Massive Transfusion

Initiate a massive transfusion protocol when the estimated blood loss exceeds 1,500 mL. 18
In cases of severe bleeding, transfusion should not be delayed while awaiting laboratory results; treatment must be guided by the clinical picture. 18

Transfusion Strategy and Hemostatic Targets

After transfusing four units of packed red blood cells, give four units of fresh‑frozen plasma and maintain a 1:1:1 ratio of packed RBCs : FFP : platelets. (Supported by both 18 and 19)
During active hemorrhage, aim for a hemoglobin > 8 g/dL and a fibrinogen level ≥ 2 g/L. 18

Antibiotic Prophylaxis

Prophylactic antibiotics should be re‑dosed when blood loss exceeds 1,500 mL. 18

Mechanical Hemorrhage Control

Pelvic packing provides rapid stabilization of uncontrolled hemorrhage and can safely remain in place for up to 24 hours when the abdomen is left open and ventilatory support is provided. 18

Interventional Radiology

Arterial embolization is indicated when a single bleeding source cannot be identified, provided the patient is hemodynamically stable enough for transfer to an interventional suite. 18

Surgical Hemostatic Techniques

Uterine compression sutures (e.g., B‑Lynch or similar brace sutures) are an effective stepwise surgical option for refractory uterine atony. 18
Hypogastric (internal iliac) artery ligation can be employed by experienced surgeons; although technically demanding and time‑consuming, it offers effective hemorrhage control when performed correctly. 18

Adjunctive Pharmacologic Therapy

Recombinant activated factor VIIa may be considered as a rescue therapy for severe refractory bleeding after hysterectomy when conventional measures have failed; it carries an approximate 3 % risk of thrombotic complications. 19

Monitoring and Re‑operation Threshold

Maintain a low threshold for returning to the operating room if ongoing bleeding is suspected, even after initial hemostatic measures have been applied. 18

Duration of Surgical Antibiotic Prophylaxis

Recommended Timing for Prophylaxis

Surgical antibiotic prophylaxis should be limited to short‑term peri‑operative administration (generally ≤ 24 hours) and is not intended for continued dosing during postoperative complications such as postpartum hemorrhage. 20

Postpartum Hemorrhage: Evidence‑Based Management of Acute Complications

Hemodynamic & Fluid Management

Aggressive crystalloid resuscitation can cause pulmonary edema and third‑spacing, worsening maternal outcomes; therefore fluid volumes should be limited and balanced with blood products. 21
Warmed physiologic electrolyte solutions should be administered while maintaining core temperature > 36 °C to support coagulation and reduce hypothermia‑related coagulopathy. 21

Transfusion Strategy

When blood loss exceeds 1,500 mL or ≥ 4 units of packed red cells, a massive transfusion protocol using a 1:1:1 ratio of red cells, fresh‑frozen plasma, and platelets is recommended. 21
Transfusion should not be delayed for laboratory results; clinical signs of shock dictate immediate component therapy. 21

Organ Dysfunction Monitoring

Prolonged hypoperfusion may lead to acute renal failure; urine output and creatinine should be monitored closely. 21
Ischemic hepatic injury can occur during sustained shock; liver enzymes and mental status require serial assessment. 21
Sheehan syndrome (post‑partum pituitary necrosis) may manifest weeks to months after severe hypoperfusion and should be screened for in affected women. 21

Temperature & Metabolic Management

Normothermia must be maintained by warming all infused fluids and blood products and using active skin warming, as clotting factor activity declines below 36 °C. 21
Metabolic acidosis should be avoided because it further impairs coagulation cascades. 21

Infection Prevention

The risk of infection rises markedly when blood loss exceeds 1,500 mL; prophylactic antibiotics should be re‑dosed in this setting. 21
Endometritis and sepsis are possible complications of retained placental tissue or prolonged surgery and require vigilant clinical monitoring. 21

Surgical Injury Prevention

Emergency hysterectomy or other rapid surgical interventions for hemorrhage control carry a risk of unrecognized ureteral, bladder, or bowel injury; careful intra‑operative assessment is essential. 21

Placental Management

Manual removal of the placenta should be avoided outside specialized settings unless hemorrhage is uncontrolled, to reduce the risk of severe complications. 22